These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 79898)

  • 1. In-vitro activity of new cephalosporin (HR 756) and cefazolin.
    Stratford BC
    Lancet; 1978 Sep; 2(8088):528-9. PubMed ID: 79898
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of the in-vitro activities of ceftazidime and new cephalosporins against 107 strains of Pseudomonas aeruginosa and 249 strains of cefazolin-resistant Enterobacteriaceae.
    Thabaut A; Durosoir JL; Saliou P
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():123-5. PubMed ID: 19810174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of new cephalosporin (HR 756) and cefazolin.
    Vanhoff R; Butzler JP; Yourassowsky E
    Lancet; 1978 Jul; 2(8082):209-10. PubMed ID: 78410
    [No Abstract]   [Full Text] [Related]  

  • 4. Class I beta-lactamase expression in Pseudomonas aeruginosa and cephalosporin resistance.
    Lancet; 1986 Feb; 1(8478):450-1. PubMed ID: 2868371
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical studies on cefsulodin in the field of pediatrics].
    Yanagisawa K; Yanagisawa K; Hoshina H; Ichihashi H
    Jpn J Antibiot; 1982 Nov; 35(11):2683-7. PubMed ID: 6820393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-{beta}-lactamase-producing Pseudomonas aeruginosa.
    Giske CG; Ge J; Nordmann P
    J Antimicrob Chemother; 2009 Aug; 64(2):430-1. PubMed ID: 19474066
    [No Abstract]   [Full Text] [Related]  

  • 7. Nosocomial infections with ceftazidime-resistant Pseudomonas aeruginosa: risk factors and outcome.
    Lee SC; Fung CP; Liu PY; Wang TC; See LC; Lee N; Chen SC; Shieh WB
    Infect Control Hosp Epidemiol; 1999 Mar; 20(3):205-7. PubMed ID: 10100550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbiological activity of cefazedone as compared to cefazolin and cephalothin.
    Knothe H
    Arzneimittelforschung; 1979; 29(2a):378-81. PubMed ID: 39575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftizoxime (FK749), a new cephalosporin with a potent in-vitro activity against Gram-negative bacilli.
    Ogawa M; Hama M; Takata N; Kosaki G; Suginaka H
    J Antimicrob Chemother; 1981 Jun; 7(6):673-6. PubMed ID: 6941959
    [No Abstract]   [Full Text] [Related]  

  • 10. [Multiply resistant Pseudomonas aeruginosa in the pediatric field].
    Tabuki K
    Nihon Rinsho; 1991 Oct; 49(10):2387-92. PubMed ID: 1660948
    [No Abstract]   [Full Text] [Related]  

  • 11. [Comparative study of the "in vitro" sensitivity of cefoxitin and cephalosporins].
    Torres A; Aguirre M; Ales JM
    Rev Clin Esp; 1979 Nov; 155(4):249-52. PubMed ID: 542674
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations.
    Gradelski E; Fung-Tomc J; Huczko E; Kessler RE
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():75-80. PubMed ID: 8150769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study.
    Walkty A; Decorby M; Nichol K; Karlowsky JA; Hoban DJ; Zhanel GG;
    J Antimicrob Chemother; 2008 Jul; 62(1):206-8. PubMed ID: 18385143
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
    Takeda S; Nakai T; Wakai Y; Ikeda F; Hatano K
    Antimicrob Agents Chemother; 2007 Mar; 51(3):826-30. PubMed ID: 17145788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia.
    Plant AJ; Dunn A; Porter RJ
    Expert Rev Anti Infect Ther; 2018 May; 16(5):367-368. PubMed ID: 29727213
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cefoperazone, cefsulodin and ceftazidime--3 cephalosporins active against Pseudomonas in comparison with their monobactam analogs].
    Baumgärtner M
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1983 Apr; 254(2):253-60. PubMed ID: 6326420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of moxalactam and gentamicin: in-vitro study with strains of Staphylococcus aureus and Pseudomonas aeruginosa.
    Skalova R; Hajsig D; Smerdel S
    J Antimicrob Chemother; 1982 Feb; 9(2):103-9. PubMed ID: 6460731
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical evaluation of cefsulodin in the field of pediatrics].
    Iwai N; Sasaki A; Taneda Y; Mizoguchi F; Nakamura H
    Jpn J Antibiot; 1982 Nov; 35(11):2688-98. PubMed ID: 6820394
    [No Abstract]   [Full Text] [Related]  

  • 19. Susceptibility of clinical isolates to cephalexin, cefazolin and cefotaxime.
    Gupta BL; Tahlan A; Dogra V; Rattan A; Bhujwala RA; Shriniwas
    Indian Pediatr; 1989 May; 26(5):466-71. PubMed ID: 2599615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activities of LCB10-0200, a novel siderophore cephalosporin, against the clinical isolates of Pseudomonas aeruginosa and other pathogens.
    Oh SH; Park HS; Kim HS; Yun JY; Oh K; Cho YL; Kwak JH
    Int J Antimicrob Agents; 2017 Dec; 50(6):700-706. PubMed ID: 28668680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.